

Functional expression of the serotonin 5-HT₇ receptor in human glioblastoma cell lines

¹Cécile Mahé, ¹Michel Bernhard, ¹Ionel Bobirnac, ¹Corinna Keser, ¹Erika Loetscher, ¹Dominik Feuerbach, ¹Kumlesh K. Dev & ^{*}¹Philippe Schoeffter

¹Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, WSJ-386.7.44, CH-4002 Basel, Switzerland

1 Serotonin 5-HT₇ receptors are present in astrocytes. Understanding their role in this type of cell would greatly benefit from the identification of astroglial cell lines expressing this receptor type.

2 The aim of the present study was to assess the expression of native 5-HT₇ receptors and 5-HT₇ receptor mRNA in a number of human glioblastoma cell lines, by means of cAMP measurements, Western blot analysis and reverse transcriptase–polymerase chain reaction (RT–PCR) analysis.

3 5-Hydroxytryptamine (5-HT), 5-carboxamidotryptamine (5-CT), 5-methoxytryptamine (5-MeOT) and 8-hydroxy-2-(di-*n*-propylamino)tetralin (8-OH-DPAT) induced concentration-dependent stimulations of cAMP accumulation in the human glioblastoma cell lines, U-373 MG, U-138 MG, U-87 MG, DBTRG-05MG, T98G, H4, CCF-STTG1 and Hs 683. The rank order of potency was 5-CT > 5-HT = 5-MeOT ≫ 8-OH-DPAT.

4 The effect of 5-CT was inhibited in a concentration-dependent manner by the selective 5-HT₇ receptor antagonist SB-269970 in all human glioblastoma cells. Schild analyses yielded slope factors close to unity (0.89–1.13) and pA₂ values of 8.69–9.05.

5 Western blot analysis revealed the presence of immunoreactive bands corresponding to the human 5-HT₇ receptor in extracts of all human glioblastoma cell lines.

6 The presence of the three splice variants of the 5-HT₇ receptor (5-HT_{7(a/b/d)}) was visualized by RT–PCR analysis with specific primers in all human glioblastoma cell lines.

7 In conclusion, human glioblastoma cell lines express functional 5-HT₇ receptors and the three splice variants of the corresponding mRNA. These cell lines could serve as model systems of native 5-HT₇ receptors in glial cells to investigate their putative role in processes like release of neurotrophic factors or inflammatory cytokines.

British Journal of Pharmacology (2004) **143**, 404–410. doi:10.1038/sj.bjp.0705936

Keywords: 5-HT₇ receptor; human glioblastoma; astrocytes; glial cells; SB-269970

Abbreviations: CHO, Chinese hamster ovary; 5-CT, 5-carboxamidotryptamine; 5-HT, 5-hydroxytryptamine, serotonin; 5-MeOT, 5-methoxytryptamine; 8-OH-DPAT, 8-hydroxy-2-(di-*n*-propylamino)tetralin; RT–PCR, reverse transcriptase–polymerase chain reaction; SB-269970, (*R*)-3-(2-(2-(4-methylpiperin-1-yl)-ethyl)pyrrolidine-1-sulphonyl)phenol

Introduction

Receptors for serotonin (5-hydroxytryptamine (5-HT)) are classified into seven major classes (5-HT_{1–7}), based on structural, functional and pharmacological criteria (Hoyer *et al.*, 1994). The 5-HT₇ receptor, cloned from mouse (Plassat *et al.*, 1993), rat (Lovenberg *et al.*, 1993; Meyerhof *et al.*, 1993; Ruat *et al.*, 1993; Shen *et al.*, 1993), guinea-pig (Tsou *et al.*, 1994) and human (Bard *et al.*, 1993), is positively coupled to adenylyl cyclase and cAMP accumulation through the stimulatory G protein G_s and displays a unique pharmacological profile which is consistent across species. Sequence alignment shows a high degree of interspecies homology (95%) but a low overall homology (<40%) with other 5-HT receptors. A number of splice variants of both the human (5-HT_{7(a/b/d)}) and rat (5-HT_{7(a/b/c)}) receptors have been identified.

They display similar pharmacological and functional characteristics when expressed in cell lines, and a similar tissue distribution (Heidmann *et al.*, 1997; Jasper *et al.*, 1997; Krobert *et al.*, 2001). The most abundant isoform (5-HT_{7(a)}) consists of a 445-amino-acid polypeptide with a relatively short third intracellular loop and a long carboxy-terminus.

The 5-HT₇ receptor mRNA has been found in the brain, where it is located in the thalamus, hypothalamus and various limbic and cortical regions in rat (Lovenberg *et al.*, 1993; Ruat *et al.*, 1993; Shen *et al.*, 1993), guinea-pig (To *et al.*, 1995) and man (Bard *et al.*, 1993; Hagan *et al.*, 2000), as well as in smooth muscles from cardiovascular and gastrointestinal tissues (Bard *et al.*, 1993; Schoeffter *et al.*, 1996; Hagan *et al.*, 2000). Receptor distribution and pharmacological studies have suggested that 5-HT₇ receptors may play a role in the control of circadian rhythms (Lovenberg *et al.*, 1993; Ying & Rusak, 1997) and smooth muscle tone (Eglen *et al.*, 1997). As far as the nervous system is concerned, selective 5-HT₇ receptor ligands may have potential therapeutic applications in sleep

*Author for correspondence;

E-mail: philippe.schoeffter@pharma.novartis.com

Advance online publication: 31 August 2004

disorders, depression, migraine and pain (for a review, see Thomas & Hagan, 2004).

Electrophysiological studies have shown that 5-HT₇ receptors modulate neuronal function in slices of rat hippocampus (Bacon & Beck, 2000; Gill *et al.*, 2002) and thalamus (Chapin & Andrade, 2001; Goillard & Vincent, 2002). Besides this neuronal localization, there is also evidence that 5-HT₇ receptors are present in glial cells. Primary cultures of rat (Shimizu *et al.*, 1996; Hirst *et al.*, 1997) and human (Cohen *et al.*, 1999) brain astrocytes express these receptors. Glial 5-HT₇ receptors have also been detected *in situ* in the mouse suprachiasmatic nucleus by electron microscopic immunocytochemistry (Belenky & Pickard, 2001). Although astrocytes have long been regarded as neuron-supporting, ancillary cells in the brain, their active role in reciprocal neuron–glia interactions is being increasingly recognized. They now appear to be regulators of synaptic activity, synaptogenesis and neurogenesis. However, the molecular pathways involved in this regulatory activity are poorly understood (for a review, see Ransom *et al.*, 2003).

In this context, the knowledge of the role of astroglial 5-HT₇ receptors would greatly benefit from the identification of cell lines expressing this receptor type, as has been the case with rat C₆ glioma cells for the 5-HT_{2A} receptor (Elliott *et al.*, 1995). It was the aim of the present study to assess the expression of native 5-HT₇ receptors and 5-HT₇ receptor mRNA in a number of human glioblastoma cell lines, by means of cAMP measurements, Western blot analysis and reverse transcriptase–polymerase chain reaction (RT–PCR) analysis.

Methods

Cell lines and culture

The human glioblastoma cell lines, U-373 MG, U-138 MG, U-87 MG, DBTRG-05MG, T98G, H4, CCF-STTG1 and Hs 683 were purchased from the American Type Culture Collection (Rockville, MD, U.S.A.). Dulbecco's modified Eagle medium (DMEM), minimum essential medium (MEM), RPMI 1640 medium and non-essential amino acids were purchased from Gibco BRL Life Technologies (Rockville, MD, U.S.A.). The glioblastoma cell lines U-373 MG, U-138 MG, U-87 MG, T98G and DBTRG-05MG were maintained in MEM, supplemented with non-essential amino acids, the H4 and Hs 683 cell lines in DMEM and the CCF-STTG1 cell line in RPMI 1640 medium. All media were supplemented with 10% foetal calf serum, penicillin G (100 U ml⁻¹) and streptomycin (100 µg ml⁻¹). Cells were grown at 37°C in a humidified atmosphere containing 5% CO₂. For cAMP measurements, the cells were subcultured in 24-well plates. For RT–PCR and Western blot experiments, cells were subcultured in six-well culture plates.

cAMP measurements and analysis of data

cAMP accumulation was measured in intact cells seeded in 24-well plates, using the standard [³H]adenine prelabelling technique, as described previously (Schoeffter *et al.*, 1997; 1999). Cells were deprived of serum 24 h before the assay. They were incubated with agonists/antagonists for 15 min in the presence of 1 mM isobutylmethylxanthine. The [³H]cAMP/

([³H]cAMP + [³H]ATP) d.p.m. ratio (cAMP conversion rate) was calculated for each sample. Concentration–response curves were fitted to the nonlinear logistic function of the Origin 6.1 software package (OriginLab Corporation, Northampton, MA, U.S.A.). *E*_{max} and EC₅₀ values were derived from these analyses. Results are given as mean values ± s.e.m. of the indicated *n* number of experiments. The pA₂ values of the antagonist compound (*R*)-3-(2-(2-(4-methylpiperin-1-yl)ethyl)pyrrolidine-1-sulphonyl)phenol (SB-269970) were estimated from Schild analyses (Arunlakshana & Schild, 1959). Incomplete curves in the presence of the highest concentration of the antagonist were constrained to the *E*_{max} of the control curve to obtain EC₅₀ estimates.

Western blot analysis

Cells were first washed twice with cold phosphate-buffered saline and then scraped in 100 µl of a buffer containing 20 mM Tris at pH 8, 137 mM NaCl, 1% Nonidet P40, 10% glycerol, 0.5 mM orthovanadate, 1 mM phenylmethane sulphonyl fluoride and a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), sonicated and centrifuged at 13,000 r.p.m. for 5 min at 4°C. The proteins (25 µg per lane) were separated by sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS–PAGE) on a 4–20% Tris–glycine polyacrylamide gel (Cambrex, Rockland, ME, U.S.A.) and transferred onto a PVDF membrane. The membranes were blocked with blocking buffer, consisting of 5% milk, 1% BSA in TBST buffer (0.2 mM Tris–HCl, pH 7.5, 150 mM NaCl and 0.05% Tween 20) and then incubated for 2 h with a rabbit polyclonal antibody to the serotonin 5-HT₇ receptor (Imgenex, San Diego, CA, U.S.A.) diluted in TBST to a final concentration of 0.5 µg ml⁻¹. This antibody was raised against a sequence identical for all human receptor splice variants. Membranes were then washed and incubated for 1 h with an anti-rabbit peroxidase-conjugated antibody (Sigma-Aldrich, Buchs, Switzerland) diluted 1:100,000 in blocking buffer, followed by application of an enhanced chemiluminescent system (Socochim SA Supersignal[®] West Femto, Pierce, Perbio Science, Lausanne, Switzerland).

Primers for polymerase chain reaction (PCR)

To identify the three splice variants of the human 5-HT₇ receptor (which differ from each other only by their carboxy-terminus tails), primers were designed in such a way that the length of the amplification products was specific to each splice variant:

Gene name	Accession number	Length of amplification product (bp)
5-HT _{7(a)}	NM_000872	506
5-HT _{7(b)}	NM_019860	546
5-HT _{7(d)}	U68488	639

The sequences of the primers were as follows:

Primer	Sequence
Forward primer:	5' CCT TCA TCT GTG GCA CTT CC 3'
Reverse primer:	5' GGT GTG CTT ACT GCT GAG AT 3'

RNA extraction and RT-PCR analysis

Total RNA was isolated from glioblastoma cell lines by using the SNAP™ Total RNA Isolation Kit (Invitrogen, Carlsbad, CA, U.S.A.). The quantity of total RNA was determined by Ribogreen® staining (Ribogreen™ RNA Quantitation Kit; Molecular Probes, Inc., Eugene, OR, U.S.A.). The quality of the RNA was checked by electrophoretic separation of the RNA on a 1.2% SeaKem LE agarose gel (Karlan, Santa Rosa, CA, U.S.A.). For each RNA sample, 400 ng of total RNA was first digested with DNase I (Qiagen, Hilden, Germany) in order to remove traces of genomic DNA contamination. The DNase I enzyme was inactivated by addition of EDTA and heating up to 65°C for 2 min. DNase I-treated total RNA was reverse transcribed into cDNA for 60 min at 42°C with 300 ng of random hexamer primers and 50 U of StrataScript™ reverse transcriptase (Stratagene, La Jolla, CA, U.S.A.). The reaction was stopped by heating up to 95°C for 5 min. In all, 20 ng of RNA/cDNA was used as template for the PCR. PCR amplification was performed in a final volume of 20 µl containing 130 µM of dNTPs, 0.5 µM of each primers, 1 U of Taq DNA polymerase (Amersham Biosciences Europe, Otefingen, Switzerland) and its corresponding buffer. The PCR amplification took place in a Biometra thermocycler with the following conditions: initial denaturation at 95°C for 5 min, then 40 cycles with the following profile: 95°C for 40 s, 60°C for 40 s and 72°C for 40 s, final extension at 72°C for 7 min. After amplification, the PCR products were separated electrophoretically on a 3% NuSieve 3:1 agarose gel and visualized by ethidium bromide staining. Each RT-PCR product was excised from agarose gels, extracted and purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The eluted DNA fragments were sequenced by A Wanner (Novartis Sequencing Facility).

Drugs

5-Hydroxytryptamine creatinine sulphate (5-HT), 5-carboxamidotryptamine maleate (5-CT) and 8-hydroxy-2-(di-*n*-propylamino)tetralin hydrobromide (8-OH-DPAT) were obtained from Sigma-Aldrich (Buchs, Switzerland). 5-Methoxytryptamine (5-MeOT) and (SB-269970) hydrochloride were synthesized at Novartis Pharma AG, Basel. Millimolar stock solutions of test compounds were made on the day of the

experiment in dimethylsulphoxide or distilled water. Further dilutions were made in distilled water.

Results

Identification of functional 5-HT₇-like receptors in human glioblastoma cell lines by cAMP measurements

A series of human glioblastoma cell lines (U-373 MG, U-138 MG, U-87 MG, DBTRG-05MG, T98G, H4, CCF-STTG1 and Hs 683) were examined for their cAMP response to 5-HT. The basal cAMP conversion rate (see Methods) ranged from 0.23×10^{-3} (U-373 MG cells) to 0.72×10^{-3} (U-138 MG cells). Stimulation of cAMP accumulation by 5-HT was observed in all cells, maximal effects varying from 1.7- (CCF-STTG1 cells) to 33-fold (H4 cells) increases above basal levels (Table 1).

Concentration-response relationships for cAMP stimulation were obtained using the four agonists 5-HT, 5-CT, 5-MeOT and 8-OH-DPAT. Results with U-373 MG, DBTRG-05MG, T98G and H4 cells are illustrated in Figure 1. The rank order of potency was 5-CT > 5-HT = 5-MeOT ≫ 8-OH-DPAT in these cell lines. Similar potencies were found for 5-CT and 5-HT in U-138 MG, U-87 MG, CCF-STTG1 and Hs 683 (Table 1).

The potent and selective 5-HT₇ receptor antagonist SB-269970 (10 nM–1 µM) induced incremental shifts in the concentration-response curve of 5-CT to the right in a parallel manner in all cell lines. Data with U-373 MG, DBTRG-05MG, T98G and H4 cells are illustrated in Figure 2. Schild analyses yielded slope factors close to unity (0.89–1.13) and pA₂ values in the range 8.69–9.05 (Table 1).

Western blot analysis

Western blot analysis was performed to investigate the occurrence of the 5-HT₇ receptor protein in human glioblastoma cells. The antiserum revealed two bands with apparent molecular masses of approximately 45 and 50 kDa in extracts of Chinese hamster ovary (CHO) cells stably transfected with the human 5-HT_{7(a)} receptor cDNA, but not in untransfected CHO cells (Figure 3a). These two bands were also present in extracts of all the human glioblastoma cell lines tested, with the exception of Hs 683 cells for which only the 50 kDa band was

Table 1 Maximal effects (E_{max}) of 5-HT for stimulation of cAMP accumulation, pEC_{50} values of 5-HT, 5-CT, 5-MeOT and 8-OH-DPAT and pA₂ values of SB-269970 versus 5-CT in human glioblastoma cell lines

Cell line	E_{max} (5-HT) Fold basal	5-HT	5-CT	pEC_{50} 5-MeOT	8-OH-DPAT	pA ₂ SB-269970
U-373 MG	9.5 ± 0.5	6.09 ± 0.12	6.98 ± 0.03	5.89 ± 0.09	<4	8.82 ± 0.05
DBTRG-05MG	8.3 ± 0.3	6.18 ± 0.07	7.22 ± 0.09	6.13 ± 0.03	<4	8.95 ± 0.05
T98G	12.9 ± 1.5	5.86 ± 0.06	6.84 ± 0.03	5.59 ± 0.06	<4	8.81 ± 0.13
H4	32.7 ± 0.9	6.03 ± 0.03	7.03 ± 0.06	5.65 ± 0.02	<4	8.92 ± 0.06
U-138 MG	7.6 ± 1.5	5.69 ± 0.04	6.58 ± 0.08	ND	ND	9.05 ± 0.07
U-87 MG	2.0 ± 0.1	6.09 ± 0.04	7.09 ± 0.03	ND	ND	8.69 ± 0.05
CCF-STTG1	1.7 ± 0.1	6.26 ± 0.05	7.33 ± 0.08	ND	ND	8.98 ± 0.04
Hs 683	1.9 ± 0.2	6.11 ± 0.17	7.32 ± 0.08	ND	ND	8.75 ± 0.10

Data are mean values ± s.e.m. from three or four individual experiments. Maximal effects are expressed as fold increases above basal cAMP accumulation. Since no maximum was reached for 8-OH-DPAT (see Figure 1), pEC_{50} values for this agonist are rough estimates. ND, not determined.




Figure 1 Concentration–response curves of 5-CT, 5-HT, 5-MeOT and 8-OH-DPAT for stimulation of cAMP accumulation in (a) U-373 MG, (b) DBTRG-05MG, (c) T98G and (d) H4 cells. Data are mean values \pm s.e.m. from three individual experiments. Results are expressed as percentage of basal cAMP accumulation.

apparent (Figure 3b). This pattern of data was observed in at least two independent experiments for each cell line.

Reverse transcriptase–polymerase chain reaction (RT–PCR)

The presence of the different splice variants of the 5-HT₇ receptor was investigated by RT–PCR analysis with specific primers that give specific amplification products for each of them (5-HT_{7(a)}, 5-HT_{7(b)} and 5-HT_{7(d)}). As a control, the cDNA of the constitutively expressed β -actin gene was also amplified. Three cDNA bands of the expected sizes (506 bp for 5-HT_{7(a)}, 546 bp for 5-HT_{7(b)} and 639 bp for 5-HT_{7(d)}) were amplified in the reverse transcribed products from all human glioblastoma cell lines tested (Figure 4). The band corresponding to the 5-HT_{7(d)} splice variant consistently appeared to be less intense than the others. The different bands obtained for each cell line were excised, re-amplified with the same primers and

sequenced. Sequencing confirmed that the PCR products corresponded to the amplification of the three cDNA splice variants in all cell lines. This pattern of data was observed in at least two independent experiments for each cell line.

Discussion

The objective of the present study was to assess the validity of human glioblastoma cell lines as model systems for the study of 5-HT₇ receptors in astroglial cells. Functional 5-HT₇ receptors and 5-HT₇ receptor mRNA are known to be present and expressed in human and rat brain astrocytes (Shimizu *et al.*, 1996; Hirst *et al.*, 1997; Cohen *et al.*, 1999). However, such primary cells cannot be propagated in culture and are therefore of limited help for extensive and detailed investigations. The present results show that several human glioblastoma cell lines (U-373 MG, U-138 MG, U-87 MG,




Figure 2 Concentration–response curves of 5-CT in the absence (control) and in the presence of 10 nM, 0.1 and 1 μ M SB-269970 in (a) U-373 MG, (b) DBTRG-05MG, (c) T98G and (d) H4 cells. Data are mean values \pm s.e.m. from three or four individual experiments. Results are expressed as percentage of basal cAMP accumulation.

DBTRG-05MG, T98G, H4, CCF-STTG1 and Hs 683) express native, functional 5-HT₇ receptors coupled to cAMP accumulation. These receptors could also be visualized by immunodetection (Western blotting) and the corresponding mRNA by RT-PCR.

In functional studies with human glioblastoma cells, the rank order of agonist potency for stimulation of cAMP accumulation was 5-CT > 5-HT = 5-MeOT \gg 8-OH-DPAT. This is the 'fingerprint' of 5-HT₇ receptors. Of the three 5-HT receptor classes positively coupled to adenylyl cyclase (5-HT₄, 5-HT₆ and 5-HT₇), 5-HT₇ is the only one showing higher affinity for 5-CT than for 5-HT (see Hoyer *et al.*, 1994). The relatively low pEC_{50} values of agonists in glioblastoma cells, as compared to their affinities for the cloned 5-HT₇ receptor (Bard *et al.*, 1993), are probably to be ascribed to a limited number of receptors in the former situation. In line with this view, it is pertinent to say that no specific radioligand binding could be detected in human glioblastoma cells, using [³H]-5-HT, [³H]-5-CT, [³H]-lysergic acid diethylamide or [³H]-mesulergine (C. Mahé, personal observations). Also, similar agonist pEC_{50} values to those reported in the present study

have been observed at native 5-HT₇ receptors in rat primary astrocytes (Hirst *et al.*, 1997).

Definitive evidence that the effect of 5-CT is mediated by 5-HT₇ receptors in human glioblastoma cells was shown in antagonist studies with SB-269970. This compound has been introduced as a potent and selective 5-HT₇ receptor antagonist, with a pK_i value of 8.9 and a functional pA_2 value of 8.5 (Hagan *et al.*, 2000; Lovell *et al.*, 2000). Values of pA_2 found in human glioblastoma cells (8.69–9.05) were quite in line with these reported data.

To confirm the expression of 5-HT₇ receptors in the human glioblastoma cells, the presence of this protein was then investigated by Western blotting, using a specific antibody raised against a sequence identical for all human receptor splice variants. Two bands, with apparent molecular masses of approximately 45 and 50 kDa, were detected for all glioblastoma cells except for Hs 683 cells, in which only the upper band was observed. These two bands were also present in CHO cells stably transfected with the human 5-HT₇ receptor cDNA. The 45–50 kDa range corresponds to the anticipated molecular mass of the 5-HT₇ receptor, which in addition




Figure 3 Western blot analysis of human glioblastoma cell and control cell extracts. (a) Lane 1, untransfected CHO cells; lanes 2 and 3, CHO cells transfected with the human 5-HT_{7(a)} receptor. (b) Lane 1, untransfected CHO cells; lane 2, T98G cells; lane 3, H4 cells; lane 4, U-373 MG cells; lane 5, U-138 MG cells; lane 6, DBTRG-05MG cells; lane 7, U-87 MG cells; lane 8, Hs 683 cells; lane 9, CCF-STTG1 cells. Molecular mass markers (in kDa) are indicated on the left.

possesses two putative sites for N-linked glycosylation in its amino-terminal region and several putative sites for phosphorylation (Boess & Martin, 1994). The results suggest that two protein forms of the 5-HT₇ receptor are expressed in human glioblastoma cells (and control CHO cells), perhaps with different degrees of glycosylation and/or phosphorylation. For some reason, Hs 683 cells do not express one of these forms.

Pharmacological and immunological detection of 5-HT₇ receptors in human glioblastoma cells was corroborated by results of molecular biology studies, showing the presence of the three splice variants of the human 5-HT₇ receptor. RT-PCR amplifications were conducted using specific primers designed in such a way that the length of the amplification products was specific for each splice variant of the human 5-HT₇ receptor. Three bands of the expected sizes were generated, suggesting the presence of the three splice variants in all glioblastoma cell lines. Sequencing of the different bands confirmed that the amplified fragments correspond to the cDNA sequences of the human 5-HT₇ receptor splice variants. The 5-HT_{7(a)} and 5-HT_{7(b)} splice variants seem to be predominantly expressed in all glioblastoma cells compared to the 5-HT_{7(d)} variant, in agreement with findings in some other tissues, including the brain (Heidmann *et al.*, 1997; Krobert *et al.*, 2001).

Taken together, the present results indicate that human glioblastoma cells may be used as model systems of native astroglial 5-HT₇ receptors. The physiological role of these astroglial receptors, as pointed out in earlier studies, remains speculative (Hirst *et al.*, 1997). The various 'classical' functions of glial cells include nutritive support for neurons and uptake of excess neurotransmitters and K⁺. However, glial cells now appear to be involved in a broader spectrum of neuron-




Figure 4 RT-PCR analysis of the 5-HT₇ receptor splice variants in human glioblastoma cells. Lane 1, DNA length standards of the indicated size (in base pairs, bp). (a) Lane 2, U-138 MG cells; lane 3, U-373 MG cells; lane 4, DBTRG-05MG cells; lane 5, T98G cells. (b) Lane 2, H4 cells; lane 3, U-87 MG cells. (c) Lane 2, CCF-STTG1 cells; lane 3, Hs 683 cells. Fragment sizes corresponding to amplified fragments of each of the three variants 5-HT_{7(a)} (506 bp), 5-HT_{7(b)} (546 bp) and 5-HT_{7(d)} (639 bp) are indicated on the right.

associated processes, for example, synaptogenesis, neurogenesis and neuroinflammation (Ransom *et al.*, 2003). Since 5-HT₇ receptors are positively linked to cAMP accumulation, cellular events associated with the cAMP/protein kinase A pathway in glial cells may be considered as candidate functions of these receptors. Interestingly enough, among these are the release of neurotrophic factors and of inflammatory cytokines (Huneycutt & Benveniste, 1995).

In conclusion, human glioblastoma cell lines express functional 5-HT₇ receptors and the three splice variants of the corresponding mRNA. These cell lines could serve as model systems of native 5-HT₇ receptors in glial cells to investigate their putative role in processes like release of neurotrophic factors or inflammatory cytokines.

We are indebted to Dr Bernard Bucher (CNRS UMR 7034, France) for helpful discussions and to Dr Daniel Hoyer (Novartis Pharma, NIBR Basel) for carefully reading the manuscript.

References

- ARUNLAKSHANA, O. & SCHILD, H.O. (1959). Some quantitative uses of drug antagonists. *Br. J. Pharmacol. Chemother.*, **14**, 48–58.
- BACON, W.L. & BECK, S.G. (2000). 5-Hydroxytryptamine₇ receptor activation decreases slow afterhyperpolarization amplitude in CA3 hippocampal pyramidal cells. *J. Pharmacol. Exp. Ther.*, **294**, 672–679.
- BARD, J.A., ZGOMBICK, J., ADHAM, N., VAYSSE, P., BRANCHEK, T.A. & WEINSHANK, R.L. (1993). Cloning of a novel human serotonin receptor (5-HT₇) positively linked to adenylate cyclase. *J. Biol. Chem.*, **268**, 23422–23426.
- BELENKY, M.A. & PICKARD, G.E. (2001). Subcellular distribution of 5-HT_{1B} and 5-HT₇ receptors in the mouse suprachiasmatic nucleus. *J. Compar. Neurol.*, **432**, 371–388.
- BOESS, F.G. & MARTIN, I.L. (1994). Molecular biology of 5-HT receptors. *Neuropharmacology*, **33**, 275–317.
- CHAPIN, E.M. & ANDRADE, R. (2001). A 5-HT₇ receptor-mediated depolarization in the anterodorsal thalamus. I. Pharmacological characterization. *J. Pharmacol. Exp. Ther.*, **297**, 395–402.
- COHEN, Z., BOUCHELET, I., OLIVIER, A., VILLEMURE, J.G., BALL, R., STANIMIROVIC, D.B. & HAMEL, E. (1999). Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. *J. Cereb. Blood Flow Metabol.*, **19**, 908–917.
- EGLÉN, R.M., JASPER, J.R., CHANG, D.J. & MARTIN, G.R. (1997). The 5-HT₇ receptor: orphan found. *Trends Pharmacol. Sci.*, **18**, 104–107.
- ELLIOTT, J.M., NEWBERRY, N.R., CHOLEWINSKI, A.J., BARTRUP, J.T., BRIDDON, S.J., CAREY, J.E., FLANIGAN, T.P., NEWTON, R.A., PHIPPS, S.L., REAVLEY, A.C., SMITH, C., WIGMORE, M., GRAHAME-SMITH, D.G. & LESLIE, R.A. (1995). Characterization of the 5-hydroxytryptamine_{2A} receptor-activated cascade in rat C6 glioma cells. *Neuroscience*, **69**, 1119–1131.
- GILL, C.H., SOFFIN, E.M., HAGAN, J.J. & DAVIES, C.H. (2002). 5-HT₇ receptors modulate synchronized network activity in rat hippocampus. *Neuropharmacology*, **42**, 82–92.
- GOAILLARD, J.M. & VINCENT, P. (2002). Serotonin suppresses the slow afterhyperpolarization in rat intralaminar and midline neurons by activating 5-HT₇ receptors. *J. Physiol.*, **541**, 453–465.
- HAGAN, J.J., PRICE, G.W., JEFFREY, P., DEEKS, N.J., STEAN, T., PIPER, D., SMITH, M.I., UPTON, N., MEDHURST, A.D., MIDDLEMISS, D.N., RILEY, G.J., LOVELL, P.J., BROMIDGE, S.M. & THOMAS, D.R. (2000). Characterization of SB-269970-A, a selective 5-HT₇ receptor antagonist. *Br. J. Pharmacol.*, **130**, 539–548.
- HEIDMANN, D.E.A., METCALF, M.A., KOHEN, R. & HAMBLIN, M.W. (1997). Four 5-hydroxytryptamine₇ (5-HT₇) receptor isoforms in human and rat produced by alternative splicing: species differences due to altered intron–exon organization. *J. Neurochem.*, **68**, 1372–1381.
- HIRST, W.D., PRICE, G.W., RATTRAY, M. & WILKIN, G.P. (1997). Identification of 5-hydroxytryptamine receptors positively coupled to adenylate cyclase in rat cultured astrocytes. *Br. J. Pharmacol.*, **120**, 509–515.
- HOYER, D., CLARKE, D.E., FOZARD, J.R., HARTIG, P.R., MARTIN, G.R., MYLECHARANE, E.J., SAXENA, F.R. & HUMPHREY, P.P.A. (1994). International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacol. Rev.*, **46**, 157–203.
- HUNEYCUTT, B.S. & BENVENISTE, E.N. (1995). Regulation of astrocyte cell biology by the cAMP/protein kinase A signaling pathway. *Adv. Neuroimmunol.*, **5**, 261–269.
- JASPER, J.R., KOSAKA, A., TO, Z.P., CHANG, D.J. & EGLÉN, R.M. (1997). Cloning, expression and pharmacology of a truncated splice variant of the human 5-HT₇ receptor (h5-HT_{7(b)}). *Br. J. Pharmacol.*, **122**, 126–132.
- KROBERT, K.A., BACH, T., SYVERSVEEN, T., KVINGEDAL, A.M. & Levy, F.O. (2001). The cloned human 5-HT₇ receptor splice variants: a comparative characterization of their pharmacology, function and distribution. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **363**, 620–632.
- LOVELL, P.J., BROMIDGE, S.M., DABBS, S., DUCKWORTH, D.M., FORBES, I.T., JENNINGS, A.J., KING, F.D., MIDDLEMISS, D.N., RAHMAN, S.K., SAUNDERS, D.V., COLLIN, L.L., HAGAN, J.J., RILEY, G.J. & THOMAS, D.R. (2000). A novel, potent, and selective 5-HT₇ antagonist: (R)-3-(2-(2-(4-methylpiperin-1-yl)-ethyl)pyrrolidine-1-sulfonyl)phenol (SB-269970). *J. Med. Chem.*, **43**, 342–345.
- LOVENBERG, T.W., BARON, B.M., DE LECEA, L., MILLER, J.D., PROSSER, R.A., REA, M.A., FOYE, P.E., RACKE, M., SLONE, A.L., SIEGEL, B.W., DANIELSON, P.E., SUTCLIFFE, J.G. & ERLANDER, M.G. (1993). A novel adenylate cyclase-activating serotonin receptor (5-HT₇) implicated in the regulation of mammalian circadian rhythms. *Neuron*, **11**, 449–458.
- MEYERHOF, W., OBERMÜLLER, F., FEHR, S. & RICHTER, D. (1993). A novel rat serotonin receptor: primary structure, pharmacology, and expression pattern in distinct brain regions. *DNA Cell Biol.*, **12**, 401–409.
- PLASSAT, J.L., AMLAIKI, N. & HEN, R. (1993). Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase. *Mol. Pharmacol.*, **44**, 229–236.
- RANSOM, B., BEHAR, T. & NEDERGAARD, M. (2003). New roles for astrocytes (stars at last). *Trends Neurosci.*, **26**, 520–522.
- RUAT, M., TRAFFORT, E., LEURS, R., TARDIVEL-LACOMBE, J., DIAZ, J., ARRANG, J.M. & SCHWARTZ, J.-C. (1993). Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT₇) activating cAMP formation. *Proc. Natl. Acad. Sci. U.S.A.*, **90**, 8547–8551.
- SCHOEFFTER, P., BOBIRNAC, I., BODDEKE, E. & HOYER, D. (1997). Inhibition of cAMP accumulation via recombinant human serotonin 5-HT_{1A} receptors: considerations on receptor effector coupling across systems. *Neuropharmacology*, **36**, 429–437.
- SCHOEFFTER, P., FEUERBACH, D., BOBIRNAC, I., GAZI, L. & LONGATO, R. (1999). Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF₁) and CRF₁ receptor mRNA expression in human neuroblastoma SH-SY5Y cells. *Fund. Clin. Pharmacol.*, **13**, 484–489.
- SCHOEFFTER, P., ULLMER, C., BOBIRNAC, I., GABBIANI, G. & LÜBBERT, H. (1996). Functional, endogenously expressed 5-hydroxytryptamine 5-HT₇ receptors in human vascular smooth muscle cells. *Br. J. Pharmacol.*, **117**, 993–994.
- SHEN, Y., MONSMA JR, F.J., METCALF, M.A., JOSE, P.A., HAMBLIN, M.W. & SIBLEY, D.R. (1993). Molecular cloning and expression of a 5-hydroxytryptamine₇ serotonin receptor subtype. *J. Biol. Chem.*, **268**, 18200–18204.
- SHIMIZU, M., NISHIDA, A., ZENSHO, H. & YAMAWAKI, S. (1996). Chronic antidepressant exposure enhances 5-hydroxytryptamine₇ receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes. *J. Pharmacol. Exp. Ther.*, **279**, 1551–1558.
- THOMAS, D.R. & HAGAN, J.J. (2004). 5-HT₇ receptors. *Curr. Drug Targets CNS Neurol. Disord.*, **3**, 81–90.
- TO, Z.P., BONHAUS, D.W., EGLÉN, R.M. & JAKEMAN, L.B. (1995). Characterization and distribution of putative 5-HT₇ receptors in guinea-pig brain. *Br. J. Pharmacol.*, **115**, 107–116.
- TSOU, A.P., KOSAKA, A., BACH, C., ZUPPAN, P., YEE, C., TOM, L., ALVAREZ, R., RAMSEY, S., BONHAUS, D.W., STEFANICH, E., JAKEMAN, L., EGLÉN, R.M. & CHAN, H.W. (1994). Cloning and expression of a 5-hydroxytryptamine₇ receptor positively coupled to adenylate cyclase. *J. Neurochem.*, **63**, 456–464.
- YING, S.W. & RUSAK, B. (1997). 5-HT₇ receptors mediate serotonergic effects on light-sensitive suprachiasmatic nucleus neurons. *Brain Res.*, **755**, 246–254.

(Received April 5, 2004
Revised May 28, 2004
Accepted July 8, 2004)